The estimated Net Worth of Rolf Andrew Ramelmeier is at least $157 Tausend dollars as of 31 December 2020. Rolf Ramelmeier owns over 2,464 units of Sangamo Therapeutics Inc stock worth over $55,422 and over the last 5 years Rolf sold SGMO stock worth over $101,638.
Rolf has made over 2 trades of the Sangamo Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Rolf sold 2,464 units of SGMO stock worth $41,247 on 31 December 2020.
The largest trade Rolf's ever made was selling 3,331 units of Sangamo Therapeutics Inc stock on 24 December 2020 worth over $60,391. On average, Rolf trades about 828 units every 1 days since 2020. As of 31 December 2020 Rolf still owns at least 65,978 units of Sangamo Therapeutics Inc stock.
You can see the complete history of Rolf Ramelmeier stock trades at the bottom of the page.
Rolf's mailing address filed with the SEC is C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BLVD., BRISBANE, CA, 94005.
Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp und Inc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include: